<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Combinations of two or more oral agents with different mechanisms of action are often used for the management of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>While these combinations have customarily been taken as separate tablets, several fixed-dose single tablet combinations are now available </plain></SENT>
<SENT sid="2" pm="."><plain>These are based on bioequivalence with the separate tablets, giving similar efficacy to the separate tablets and necessitating the same cautions and contraindications that apply to each active component </plain></SENT>
<SENT sid="3" pm="."><plain>Fixed-dose combinations can offer convenience, reduce the pill burden and simplify administration regimens for the patient </plain></SENT>
<SENT sid="4" pm="."><plain>They increase patient adherence compared with equivalent combinations of separate tablets, and this is associated with some improvements in glycaemic control </plain></SENT>
<SENT sid="5" pm="."><plain>Presently available <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> fixed-dose combinations include <z:chebi fb="0" ids="6801">metformin</z:chebi> combined with a sulphonylurea, thiazolidinedione, dipeptidylpeptidase-4 inhibitor or meglitinide as well as thiazolidinedione-sulphonylurea combinations, each at a range of dosage strengths to facilitate titration </plain></SENT>
<SENT sid="6" pm="."><plain>Anticipated future expansion of multiple drug regimens for <z:mp ids='MP_0002055'>diabetes</z:mp> management is likely to increase the use of fixed-dose single tablet combinations </plain></SENT>
</text></document>